Philip Kantoff: Next Generation Radiopharmaceutical Drug Development Hopkins Biotech podcast

Artwork

Science Careers Biology Business Hopkins Biotech

Innhold levert av Hopkins Biotech Podcast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Hopkins Biotech Podcast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Hopkins Biotech Podcast « »
Philip Kantoff: Next Generation Radiopharmaceutical Drug Development

1+ y ago 37:51

Del

MP3•Episoder hjem

Innhold levert av Hopkins Biotech Podcast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Hopkins Biotech Podcast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Dr. Phil Kantoff is the CEO and Co-Founder of Convergent Therapeutics, a clinical-stage pharmaceutical company focused on developing next-generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy developed by Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine.

Prior to founding the company, Dr. Kantoff spent six years as Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center, caring for cancer patients and developing improved cancer testing and cancer therapies. He is the Emeritus Jerome and Nancy Kohlberg Chair in Medicine at Harvard Medical School, and he was the Chief of the Solid Tumor Oncology Division and Director of the Lank Center for Genitourinary Oncology, at Dana Farber Cancer Institute.

In this episode, we discuss Phil’s transition out of academic medicine, the field of radiopharmaceuticals, Convergent’s approach to drug development, and specific business considerations for a unique class of molecules.

Hosted by Joe Varriale.

… continue reading

84 episoder

#Science #Careers #Biology #Business #Hopkins Biotech

Artwork

Philip Kantoff: Next Generation Radiopharmaceutical Drug Development

Hopkins Biotech Podcast

27 subscribers

published 1+ y ago

Del

MP3•Episoder hjem

Innhold levert av Hopkins Biotech Podcast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Hopkins Biotech Podcast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Dr. Phil Kantoff is the CEO and Co-Founder of Convergent Therapeutics, a clinical-stage pharmaceutical company focused on developing next-generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy developed by Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine.

Prior to founding the company, Dr. Kantoff spent six years as Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center, caring for cancer patients and developing improved cancer testing and cancer therapies. He is the Emeritus Jerome and Nancy Kohlberg Chair in Medicine at Harvard Medical School, and he was the Chief of the Solid Tumor Oncology Division and Director of the Lank Center for Genitourinary Oncology, at Dana Farber Cancer Institute.

In this episode, we discuss Phil’s transition out of academic medicine, the field of radiopharmaceuticals, Convergent’s approach to drug development, and specific business considerations for a unique class of molecules.

Hosted by Joe Varriale.

… continue reading

84 episoder

#Science #Careers #Biology #Business #Hopkins Biotech

Alle episoder

×

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

Lytt til 500+ tema